Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Myxofibrosarcoma Indication Strategy Report 2026: PDGFR, Trials and Deals
23 July 2026
2026 Myxofibrosarcoma strategy: epidemiology, PDGFR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Dedifferentiated liposarcoma Indication Strategy Report 2026: MDM2, Trials and Deals
23 July 2026
2026 Dedifferentiated liposarcoma strategy: epidemiology, MDM2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Myxoid liposarcoma Indication Strategy Report 2026: DDIT3, Trials and Deals
23 July 2026
2026 Myxoid liposarcoma strategy: epidemiology, DDIT3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Inflammatory myofibroblastic tumor Indication Strategy Report 2026: ALK, Trials and Deals
23 July 2026
2026 Inflammatory myofibroblastic tumor strategy: epidemiology, ALK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Solitary fibrous tumor Indication Strategy Report 2026: STAT6, Trials and Deals
23 July 2026
2026 Solitary fibrous tumor strategy: epidemiology, STAT6 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dermatofibrosarcoma protuberans Indication Strategy Report 2026: PDGFRB, Trials and Deals
23 July 2026
2026 Dermatofibrosarcoma protuberans strategy: epidemiology, PDGFRB biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Alveolar soft part sarcoma Indication Strategy Report 2026: VEGFR, Trials and Deals
23 July 2026
2026 Alveolar soft part sarcoma strategy: epidemiology, VEGFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Clear cell sarcoma Indication Strategy Report 2026: MET, Trials and Deals
23 July 2026
2026 Clear cell sarcoma strategy: epidemiology, MET biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Undifferentiated pleomorphic sarcoma Indication Strategy Report 2026: PDGFR, Trials and Deals
23 July 2026
2026 Undifferentiated pleomorphic sarcoma strategy: epidemiology, PDGFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Secretory carcinoma Indication Strategy Report 2026: NTRK3, Trials and Deals
23 July 2026
2026 Secretory carcinoma strategy: epidemiology, NTRK3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Mucoepidermoid carcinoma Indication Strategy Report 2026: MAML2, Trials and Deals
23 July 2026
2026 Mucoepidermoid carcinoma strategy: epidemiology, MAML2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lacrimal gland carcinoma Indication Strategy Report 2026: MYB, Trials and Deals
23 July 2026
2026 Lacrimal gland carcinoma strategy: epidemiology, MYB biology, clinical competition, recent deals, unmet need and market attractiveness.